SLS-003 (sublingual ketamine)

About SLS-003 (sublingual ketamine)

Finished wafers manufactured using WaferiX sublingual delivery technology. WaferiX wafers increase the bioavailability of actives and disintegrate within seconds for rapid and predictable absorption and onset of action.
Finished wafers manufactured using WaferiX sublingual delivery technology. WaferiX wafers increase the bioavailability of actives and disintegrate within seconds for rapid and predictable absorption and onset of action.
  • In November 2021, Seelos licensed SLS-003 from iX Biopharma for Wafermine™ (sublingual racemic ketamine wafer) and a worldwide license for other sublingual ketamine wafers formulations.
  • SLS-003 is delivered using a proprietary fast-dissolving wafer-based drug delivery platform technology known as WaferiX™.
  • SLS-003 (sublingual ketamine wafer) focus in chronic indication where sublingual delivery is better suited and continue developing SLS-002 (intranasal racemic ketamine) in the acute setting such as ASIB in MDD.
  • Seelos plans to evaluate SLS-003, in pain indications such as chronic neuropathic pain and Complex Regional Pain Syndrome (CRPS) and in additional psychiatric disorders, including post-traumatic stress disorder (PTSD).
  • SLS-003 has Orphan Drug designation in Complex Regional Pain Syndrome (CRPS).
  • SLS-003 has already completed positive Phase II studies in other indications.